[1]任伟龙,张瑜,钱晨韵,等.不同剂量黄连素对肉鸡组织P-gp编码基因Abcb1 mRNA表达及口服恩诺沙星药动学的影响[J].南京农业大学学报,2016,39(3):488-494.[doi:10.7685/jnau.201507036]
 REN Weilong,ZHANG Yu,QIAN Chenyun,et al.The effect of berberine on the pharmacokinetics of oral enrofloxain in broilers[J].Journal of Nanjing Agricultural University,2016,39(3):488-494.[doi:10.7685/jnau.201507036]
点击复制

不同剂量黄连素对肉鸡组织P-gp编码基因Abcb1 mRNA表达及口服恩诺沙星药动学的影响()
分享到:

《南京农业大学学报》[ISSN:1000-2030/CN:32-1148/S]

卷:
39卷
期数:
2016年3期
页码:
488-494
栏目:
OA栏目
出版日期:
2016-05-06

文章信息/Info

Title:
The effect of berberine on the pharmacokinetics of oral enrofloxain in broilers
作者:
任伟龙 张瑜 钱晨韵 孙勇 杨婧 侯石桐 阮宝林 王丽平
南京农业大学动物医学院, 江苏 南京 210095
Author(s):
REN Weilong ZHANG Yu QIAN Chenyun SUN Yong YANG Jing HOU Shitong RUAN Baolin WANG Liping
College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China
关键词:
黄连素P-gp恩诺沙星mRNA表达
Keywords:
berberineP-gpenrofloxacinmRNA expression
分类号:
S859.7
DOI:
10.7685/jnau.201507036
摘要:
[目的] P-糖蛋白(P-gp,编码基因Abcb1)对口服药物生物利用度影响较大,本试验旨在探究黄连素对肉鸡组织Abcb1 mRNA表达及对恩诺沙星药动学的影响,为临床合理用药及研究药物间相互作用提供依据。[方法] 15只1月龄AA肉鸡随机分为3组:对照组和2个黄连素(40和80 mg·kg-1)处理组(n=5)。不同剂量黄连素处理AA肉鸡1 d后采集组织并用荧光定量PCR方法检测组织内Abcb1 mRNA表达的差异;另取15只1月龄AA肉鸡也随机分为对照组和2个黄连素(40和80 mg·kg-1)处理组,各组鸡处理后口服恩诺沙星10 mg·kg-1,并于不同时间点采集血液,用高效液相色谱法测定恩诺沙星的血药浓度,采用3P97软件统计其药代动力学参数。[结果] 荧光定量的结果表明:高、低剂量的黄连素处理能显著降低肾脏(P=0.021,P=0.003)、十二指肠(P=0.036,P=0.008)、空肠(P=0.028,P=0.086)和回肠(P=0.026,P=0.003)中Abcb1 mRNA的表达水平,但对肝脏Abcb1 mRNA表达无显著影响。药动学结果表明:恩诺沙星单剂量口服后在肉鸡体内的吸收速率常数(Ka)为(0.96±0.25)h-1,消除半衰期(T1/2ke)为(4.19±0.26)h,达峰时间(Tmax)为(2.66±0.45)h,血浆中峰浓度(Cmax)为(1.83±0.25) μg·mL-1,AUC0~∞AUC0~2 h分别为(21.78±1.59)和(5.30±0.45) μg·mL-1·h;40和80 mg·kg-1黄连素处理肉鸡后,能显著促进恩诺沙星在肉鸡体内的吸收,减慢其排泄过程,表现为Ka显著升高为(1.66±0.17)和(1.78±0.18)h-1,AUC0~∞AUC0~2 h显著升高为(28.04±0.54)、(29.80±1.68) μg·mL-1·h和(7.07±0.36)、(7.60±0.58) μg·mL-1·h(P<0.05),Tmax显著下降为(2.13±0.18)、(2.07±0.35 h)(P<0.05)。[结论] 不同剂量黄连素引起肉鸡各组织内P-gp编码基因Abcb1的mRNA表达量有所下降,并导致恩诺沙星吸收加快,排泄减慢,药-时曲线下面积增加。该结果可为研究黄连素作为P-gp抑制剂候选药物提供参考。
Abstract:
[Objectives] P-glycoprotein(P-gp)affects the bioavailability of oral drugs in animals. The aim of the study is to detect the effect of berberine on the mRNA expression and activity of P-gp in broilers, thus providing theoretical support for clinical rational use of drugs and drug-drug interaction.[Methods] In this study, fifteen healthy AA broilers were randomly divided into three groups, control group and two berberine(40 and 80 mg·kg-1)treated groups(n=5). The Abcb1 mRNA in different tissues of broilers was detected by real time RT-PCR. The other 15 broilers were treated as above and then orally administrated enrofloxacin at dose of 10 mg·kg-1. Blood samples were collected at different time and then the plasma concentration of enrofloxacin was detected by HPLC method. The pharmacokinetic parameters of enrofloxacin were evaluated from the plasma drug concentrations using software 3P97.[Results] The real time RT-PCR showed that berberine at dose of 80 and 40 mg·kg-1 significantly inhibited Abcb1 mRNA in duodenum(P=0.036, P=0.008), ileum(P=0.026, P=0.003)and kidney(P=0.021, P=0.003). Berberine significantly inhibited Abcb1 mRNA in jejumn at dose of 80 mg·kg-1(P=0.028). The results of HPLC showed that in control group, the parameter Ka was(0.96±0.25)h-1, T1/2 was(4.19±0.26)h, Tmax was(2.66±0.45)h, Cmax was(1.83±0.25) μg·mL-1, AUC0-∞and AUC0-2 h were(21.78±1.59)and(5.30±0.45) μg·mL-1·h, respectively. After treating with berberine(40 and 80 mg·kg-1), the Ka[(1.66±0.17), (1.78±0.18)h-1], T1/2ke[(5.87±0.48), (7.57±1.46)h], AUC0-∞[(28.04±0.54), (29.80±1.68) μg·mL-1·h] and AUC0-2 h[(7.07±0.36), (7.60±0.58) μg·mL-1·h]were significantly increased(P<0.05), which indicated that berberine could improve the absorption of enrofloxacin from intestine.[Conclusions] The Abcb1 mRNA expression decreased in different degrees after administrating with different doses of berberine. The rate of absorption and AUC of enrofloxacin increased, presuming that it may has relations with decreased expression of P-gp, which provided theoretical basis for studying berberine as a candidate inhibitor of P-gp.

参考文献/References:

[1] 李波,朱维良,陈凯先. 小檗碱及其衍生物的研究进展[J]. 药学学报,2008,43(8):773-787. Li B,Zhu W L,Chen K X. Advances in the study of berberine and its derivatives[J]. Acta Pharmaceutica Sinica,2008,43(8):773-787(in Chinese with English abstract).
[2] 伍奕,曾勇,梁松岳. 黄连素逆转结肠癌细胞株HCT-8/VCR多药耐药及其与P-gp功能变化相关性的探索性研究[J]. 中国医药指南,2010,8(21):18-20. Wu Y,Zeng Y,Liang S Y. The exploratory research on the berberine reverse the HCT-8/VCR multidrug resistence and its relationship with P-gp functional variance[J]. Guide of China Medicine,2010,8(21):18-20(in Chinese with English abstract).
[3] Qiu W,Jiang X H,Liu C X,et al. Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp[J]. Phytotherapy Research,2009,23(11):1553-1558.
[4] Murakami T,Takano M. Intestinal efflux transporters and drug absorption[J]. Expert Opinion on Drug Metabolism & Toxicology,2008,4(7):923-939.
[5] Juliano R L,Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochimica et Biophysica Acta,1976,455(1):152-162.
[6] 赵瑞娇,胡亚南,张凤凤,等. 恩诺沙星微囊在猪体内的药物动力学[J]. 西北农业学报,2011,20(12):11-15. Zhao R J,Hu Y N,Zhang F F,et al. Pharmacokinetics of enrofloxacin microcapsules in pigs[J]. Acta Agriculturae Boreali-Occidentalis Sinica,2011,20(12):11-15(in Chinese with English abstract).
[7] Guo M,Sun Y,Zhang Y,et al. E.coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP4503A in liver and kidney of broilers[J]. PLoS ONE,2014,9(1):e87781.
[8] Xing J Y,Kang L,Jiang Y L. Effect of dietary betaine supplementation on lipogenesis gene expression and CpG methylation of lipoprotein lipase gene in broilers[J]. Molecular Biology Reports,2011,38(3):1975-1981.
[9] Smith N F,Figg W D,Sparreboom A. Recent advances in pharmacogenetic approaches to anticancer drug development[J]. Drug Development Research,2004,62(3):233-253.
[10] Yamaoka K,Nakagawa T,Uno T. Application of Akaike’s information criterion(AIC)in the evaluation of linear pharmacokinetic equations[J]. Journal of Pharmacokinetics and Biopharmaceutics,1978,6(2):165-175.
[11] 史成军,符立梧. P-糖蛋白的表达和功能活性调控研究进展[J]. 药学学报,2007,42(49):911-916. Shi C J,Fu L W. Advances in the study of expression and regulation of P-glycoprotein[J]. Acta Phamaceutia Sinica,2007,42(49):911-916(in Chinese with English abstract).
[12] Zhang W,Tan T M,Lim L Y. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats[J]. Drug Metab Dispos,2007,35(1):110-115.
[13] Choi J S,Piao Y J,Kang K W. Effects of quercetin on the bioavailability of doxorubicin in rats:role of CYP3A4 and P-gp inhibition by quercetin[J]. Arch Pharm Res,2011,34(4):607-613.
[14] Shan Y Q,Ren G,Wang Y X,et al. Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux[J]. Metabolism,2013,62(3):446-456.
[15] Dautrey S,Felice K,Petiet A,et al. Active intestinal elimination of ciprofloxacin in rats:modulation by different substrates[J]. Br J Pharmacol,1999,127(7):1728-1734.
[16] Yamaguchi H,Yano I,Saito H,et al. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo[J]. J Pharmacol Exp Ther,2002,300(3):1063-1069.
[17] Hennessy M,Spiers J P. A primer on the mechanics of P-glycoprotein the multidrug transporter[J]. Pharmacol Res,2007,55(1):1-15.
[18] 韦灵玉,张玉杰,徐静静,等. 黄连黄芩配伍诱导对大鼠肠黏膜上P-gp活性的影响[J]. 中国实验方剂学杂志,2012,18(18):141-146. Wei L Y,Zhang Y J,Xu J J,et al. Induction of P-glycoprotein in rat jejunum by combined use of coptis-scute herb[J]. Chinese Journal of Experimental Traditional Medical Formulae,2012,18(8):141-146(in Chinese with English abstract).
[19] Guo Y,Pope C,Cheng X,et al. Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice[J]. J Ethnopharmacol,2011,138(1):111-118.
[20] 常宏宇,潘凯丽,马福成,等. 姜黄素、红霉素逆转K562/A02细胞多药耐药机制的研究[J]. 中华血液学杂志,2006,27(4):254-258. Chang H Y,Pan K L,Ma F C,et al. The study on reversing mechanism of multidrug resistance of K562/A02 cell line by curcumin and erythromycin[J]. Chinese Journal of Hematology,2006,27(4):254-258(in Chinese with English abstract).
[21] Suzuki H,Tanabe H,Mizukami H,et al. Selective regulation of multidrug resistance protein in vascular smooth muscle cells by the isoquinoline alkaloid coptisine[J]. Biol Pharm Bull,2010,33(4):677-682.

备注/Memo

备注/Memo:
收稿日期:2015-07-22。
基金项目:江苏省高校"青蓝工程"人才项目(2014);南京农业大学SRT计划项目(1317A25)
作者简介:任伟龙,硕士研究生。
通信作者:王丽平,博士,教授,主要从事兽医药理及毒理学研究,E-mail:wlp71@163.com。
更新日期/Last Update: 1900-01-01